<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082341</url>
  </required_header>
  <id_info>
    <org_study_id>MVDC-2008-005</org_study_id>
    <secondary_id>SPZ IRR HUMAN</secondary_id>
    <secondary_id>5R01HL086488-02</secondary_id>
    <nct_id>NCT01082341</nct_id>
  </id_info>
  <brief_title>Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites</brief_title>
  <acronym>SPZ-Irrad</acronym>
  <official_title>Phase 1 and Phase 2a Clinical Trial:Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Malaria Vaccine and Drug Development Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asoclinic Inmunología Ltda.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Malaria Vaccine and Drug Development Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is possible to safely protect human volunteers immunized with P. vivax irradiated
      sporozoites from P. vivax challenge with live sporozoites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: Phase 1 and Phase 2a Clinical Trial: Immunization of human volunteers with P. vivax
      irr-spz. (Short name: Irrad-SPZ) Population 27 healthy adult volunteers, males and
      non-pregnant females, between 18-45 years of age, who fulfill inclusion/exclusion criteria
      (described below) as determined by clinical history and serological tests. Approximately 20
      parasitized blood-donor volunteers will be required to infected Anopheles mosquitoes which
      will be used to immunize volunteers with a total of 1000-1500 infected mosquitoes, during
      8-10 months. Afterwards challenge to prove protection.

      Number of Sites: 2 Study Duration: 2 years. Subject Duration : Step1: 1-2 hours to blood
      donors; Step 2 and 3: 2 years to immunized volunteers Objectives Primary

      • To assess the safety and protective efficacy of P. vivax irradiated sporozoite vaccination.

      Secondary

        -  To determine the immune responses and duration elicited by the P. vivax challenge in
           human Fy(+) volunteers previously immunized with irr-spz, as compared with non-immunized
           human volunteers.

        -  To determine the immune responses and duration elicited by irr-spz immunization scheme
           in human Fy(+) volunteers; comparing it with the same immunization scheme with non
           irr-spz in Fy(-) participants, and also with controls exposed to the same mosquito bite
           scheme as that of immunization but using mosquitoes without parasite infection.

        -  To study new antigens potentially useful to induce pre-erythrocytic protection against
           P. vivax malaria infection
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Three groups are considered to be intervened. Experimental, Control and Fy(-) groups. Comparison will be done between E and C groups for protective efficacy. For immune response tests E vs Fy(-),E vs Fy(-), and Fy(-) vs C, pairs will be compared.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of subjects reporting any AEs, the occurrence of specifics AEs, and discontinuation due to AEs will be tabulated. Frequency of AEs will be cross-tabulated by group for each immunization session</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Fy(+)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fy(+) control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fy(-)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six Fy(-) volunteers will be exposed to infective mosquito bites.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunization with P. vivax irradiated sporozoites</intervention_name>
    <description>Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.
14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials.</description>
    <arm_group_label>Fy(+)</arm_group_label>
    <arm_group_label>Fy(+) control</arm_group_label>
    <arm_group_label>Fy(-)</arm_group_label>
    <other_name>P. vivax irradiated sporozoites vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Healthy 18 to 45 years old man or non-pregnant women.

               -  To have the capacity to sign an informed consent in a free and voluntary way.

               -  Have an acceptable understanding of the clinical trial through the approval of a
                  questionnaire regarding the information given in the consent process.

               -  Obligatory use of adequate contra-conceptive method from beginning of recruitment
                  and screening time up to three months after last immunization

               -  Do not have chronic or acute diseases. These conditions will be determined by
                  clinical history, physical exam and laboratory tests.

               -  To accept not traveling to malaria endemic areas during the clinical trial should

               -  To have telephone at home or mobile phone that permit permanent contact for
                  follow up

               -  He (she) manifest that is willing to participated during both steps of the
                  clinical trial.

        Exclusion Criteria:

          -  Volunteers with less than 18 old year or more than 45 old years.

          -  Pregnant and suckling women will be excluded. Pregnancy will be determined both by
             interview, and by serum B-subunit chorionic gonadotrophin testing.

          -  History of moderate or severe insect, or food allergies.

          -  G-6PD deficiency or any Hb genetic defect (for example; sickle cell disease)

          -  Previous malaria infection demonstrated by think smear, PCR or specific antimalarial
             antibodies.

          -  If the subject has previously participated in a malarial vaccine trial.

          -  Clinical record of allergies to drug or insect bites.

          -  Symptoms, signs or data from laboratory test that suggests to the physician any
             systemic disorder like renal, hepatic, cardiovascular, pulmonary, psychiatric
             disorders or other illnesses that could interfere with results of clinical trial or
             could compromise the health of the volunteer.

          -  To have antibodies against hepatitis C, VIH, or hepatitis B superficial antigen and/or
             hepatitis B core antibodies.

          -  To have any abnormality in the parameters assessed by blood laboratory tests.
             Base-line values will be established before initiation of the clinical trial.

          -  Presence or history of an auto-immune disease such as; Asthma, lupus, rheumatoid
             arthritis, Graves's disease, Hashimoto tyroiditis, and others.

          -  History of surgical removal of the spleen (splenectomy).

          -  Volunteer with medical treatment known to alter the immune system before 3 months to
             recruitment, such as; cortico-steroids, chemotherapeutic agents, fludarabine,
             cyclosporine, tacrolimus, mycophenolate mofetil, rapamycine, ATG, alemtuzumab.

          -  Alcoholism or drug abuse that may interfere with social relationship of individual.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Socrates Herrera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Malaria Vaccine Develepment Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Malaria Vaccine of Develepmente Center</name>
      <address>
        <city>Cali</city>
        <state>Valle</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <link>
    <url>http://inmuno.org</url>
    <description>www.inmuno.org</description>
  </link>
  <reference>
    <citation>Wang R, Arevalo-Herrera M, Gardner MJ, Bonelo A, Carlton JM, Gomez A, Vera O, Soto L, Vergara J, Bidwell SL, Domingo A, Fraser CM, Herrera S. Immune responses to Plasmodium vivax pre-erythrocytic stage antigens in naturally exposed Duffy-negative humans: a potential model for identification of liver-stage antigens. Eur J Immunol. 2005 Jun;35(6):1859-68. Erratum in: Eur J Immunol. 2005 Jun;35(6):2006.</citation>
    <PMID>15864779</PMID>
  </reference>
  <reference>
    <citation>Coban C, Ishii KJ, Horii T, Akira S. Manipulation of host innate immune responses by the malaria parasite. Trends Microbiol. 2007 Jun;15(6):271-8. Epub 2007 Apr 26. Review.</citation>
    <PMID>17466521</PMID>
  </reference>
  <reference>
    <citation>Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 2002 Apr 15;185(8):1155-64. Epub 2002 Apr 1.</citation>
    <PMID>11930326</PMID>
  </reference>
  <reference>
    <citation>Richie TL, Saul A. Progress and challenges for malaria vaccines. Nature. 2002 Feb 7;415(6872):694-701. Review.</citation>
    <PMID>11832958</PMID>
  </reference>
  <reference>
    <citation>Doolan DL, Hoffman SL, Southwood S, Wentworth PA, Sidney J, Chesnut RW, Keogh E, Appella E, Nutman TB, Lal AA, Gordon DM, Oloo A, Sette A. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity. 1997 Jul;7(1):97-112.</citation>
    <PMID>9252123</PMID>
  </reference>
  <reference>
    <citation>Mellouk S, Lunel F, Sedegah M, Beaudoin RL, Druilhe P. Protection against malaria induced by irradiated sporozoites. Lancet. 1990 Mar 24;335(8691):721.</citation>
    <PMID>1969073</PMID>
  </reference>
  <reference>
    <citation>Nussenzweig R, Vanderberg J, Most H. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. IV. Dose response, specificity and humoral immunity. Mil Med. 1969 Sep;134(10):1176-82.</citation>
    <PMID>4987036</PMID>
  </reference>
  <reference>
    <citation>Seguin MC, Klotz FW, Schneider I, Weir JP, Goodbary M, Slayter M, Raney JJ, Aniagolu JU, Green SJ. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells. J Exp Med. 1994 Jul 1;180(1):353-8.</citation>
    <PMID>7516412</PMID>
  </reference>
  <reference>
    <citation>Weiss WR. Host-parasite interactions and immunity to irradiated sporozoites. Immunol Lett. 1990 Aug;25(1-3):39-42. Review.</citation>
    <PMID>2283161</PMID>
  </reference>
  <reference>
    <citation>Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci U S A. 1988 Jan;85(2):573-6.</citation>
    <PMID>2963334</PMID>
  </reference>
  <reference>
    <citation>Collins WE, Contacos PG. Immunization of monkeys against Plasmodium cynomolgi by X-irradiated sporozoites. Nat New Biol. 1972 Apr 12;236(67):176-7.</citation>
    <PMID>4624244</PMID>
  </reference>
  <reference>
    <citation>Collins WE, Nussenzweig RS, Ballou WR, Ruebush TK 2nd, Nardin EH, Chulay JD, Majarian WR, Young JF, Wasserman GF, Bathurst I, et al. Immunization of Saimiri sciureus boliviensis with recombinant vaccines based on the circumsporozoite protein of Plasmodium vivax. Am J Trop Med Hyg. 1989 May;40(5):455-64.</citation>
    <PMID>2658634</PMID>
  </reference>
  <reference>
    <citation>Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ. 1979;57 Suppl 1:165-73.</citation>
    <PMID>120766</PMID>
  </reference>
  <reference>
    <citation>Zavala F, Cochrane AH, Nardin EH, Nussenzweig RS, Nussenzweig V. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J Exp Med. 1983 Jun 1;157(6):1947-57.</citation>
    <PMID>6189951</PMID>
  </reference>
  <reference>
    <citation>Egan JE, Hoffman SL, Haynes JD, Sadoff JC, Schneider I, Grau GE, Hollingdale MR, Ballou WR, Gordon DM. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 1993 Aug;49(2):166-73.</citation>
    <PMID>8357078</PMID>
  </reference>
  <reference>
    <citation>Clyde DF. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. Bull World Health Organ. 1990;68 Suppl:9-12. Review.</citation>
    <PMID>2094597</PMID>
  </reference>
  <reference>
    <citation>Clyde DF, McCarthy VC, Miller RM, Hornick RB. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci. 1973 Dec;266(6):398-403.</citation>
    <PMID>4590095</PMID>
  </reference>
  <reference>
    <citation>Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci. 1973 Sep;266(3):169-77.</citation>
    <PMID>4583408</PMID>
  </reference>
  <reference>
    <citation>Clyde DF. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg. 1975 May;24(3):397-401.</citation>
    <PMID>808142</PMID>
  </reference>
  <reference>
    <citation>Rieckmann KH. Human immunization with attenuated sporozoites. Bull World Health Organ. 1990;68 Suppl:13-6.</citation>
    <PMID>2094578</PMID>
  </reference>
  <reference>
    <citation>Rieckmann KH, Beaudoin RL, Cassells JS, Sell KW. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ. 1979;57 Suppl 1:261-5.</citation>
    <PMID>120773</PMID>
  </reference>
  <reference>
    <citation>Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW. Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg. 1974;68(3):258-9.</citation>
    <PMID>4608063</PMID>
  </reference>
  <reference>
    <citation>Herrington D, Davis J, Nardin E, Beier M, Cortese J, Eddy H, Losonsky G, Hollingdale M, Sztein M, Levine M, et al. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg. 1991 Nov;45(5):539-47.</citation>
    <PMID>1951863</PMID>
  </reference>
  <reference>
    <citation>Krzych U, Lyon JA, Jareed T, Schneider I, Hollingdale MR, Gordon DM, Ballou WR. T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. J Immunol. 1995 Oct 15;155(8):4072-7.</citation>
    <PMID>7561118</PMID>
  </reference>
  <reference>
    <citation>Glynn JR. Infecting dose and severity of malaria: a literature review of induced malaria. J Trop Med Hyg. 1994 Oct;97(5):300-16. Review.</citation>
    <PMID>7932927</PMID>
  </reference>
  <reference>
    <citation>Glynn JR, Collins WE, Jeffery GM, Bradley DJ. Infecting dose and severity of falciparum malaria. Trans R Soc Trop Med Hyg. 1995 May-Jun;89(3):281-3.</citation>
    <PMID>7660433</PMID>
  </reference>
  <reference>
    <citation>Powell RD, McNamara JV. Infection with chloroquine-resistant Plasmodium falciparum in man: prepatent periods, incubation periods, and relationships between parasitemia and the onset of fever in nonimmune persons. Ann N Y Acad Sci. 1970 Oct 30;174(2):1027-41.</citation>
    <PMID>4993529</PMID>
  </reference>
  <reference>
    <citation>Chulay JD, Schneider I, Cosgriff TM, Hoffman SL, Ballou WR, Quakyi IA, Carter R, Trosper JH, Hockmeyer WT. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg. 1986 Jan;35(1):66-8.</citation>
    <PMID>3511753</PMID>
  </reference>
  <reference>
    <citation>Bejon P, Andrews L, Andersen RF, Dunachie S, Webster D, Walther M, Gilbert SC, Peto T, Hill AV. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis. 2005 Feb 15;191(4):619-26. Epub 2005 Jan 7.</citation>
    <PMID>15655787</PMID>
  </reference>
  <reference>
    <citation>van Dijk MR, Douradinha B, Franke-Fayard B, Heussler V, van Dooren MW, van Schaijk B, van Gemert GJ, Sauerwein RW, Mota MM, Waters AP, Janse CJ. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12194-9. Epub 2005 Aug 15.</citation>
    <PMID>16103357</PMID>
  </reference>
  <reference>
    <citation>Hurtado S, Salas ML, Romero JF, Zapata JC, Ortiz H, Arevalo-Herrera M, Herrera S. Regular production of infective sporozoites of Plasmodium falciparum and P. vivax in laboratory-bred Anopheles albimanus. Ann Trop Med Parasitol. 1997 Jan;91(1):49-60.</citation>
    <PMID>9093429</PMID>
  </reference>
  <reference>
    <citation>Zapata JC, Perlaza BL, Hurtado S, Quintero GE, Jurado D, González I, Druilhe P, Arévalo-Herrera M, Herrera S. Reproducible infection of intact Aotus lemurinus griseimembra monkeys by Plasmodium falciparum sporozoite inoculation. J Parasitol. 2002 Aug;88(4):723-9.</citation>
    <PMID>12197121</PMID>
  </reference>
  <reference>
    <citation>Herrera, S., et al., Development of a sporozoite challenge model for Plasmodium vivax in human volunteers. . (Submitte), 2009</citation>
  </reference>
  <reference>
    <citation>Herrera, S., et al., Implication of Plasmdium vivax sporozoite challenge system in vaccine development, in International Research in Infectious Diseases. 2007. p. 53.</citation>
  </reference>
  <reference>
    <citation>Herrera S, De Plata C, González M, Perlaza BL, Bettens F, Corradin G, Arévalo-Herrera M. Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing P. vivax CS epitopes in Aotus monkeys. Parasite Immunol. 1997 Apr;19(4):161-70.</citation>
    <PMID>9149283</PMID>
  </reference>
  <reference>
    <citation>Herrera S, Bonelo A, Perlaza BL, Valencia AZ, Cifuentes C, Hurtado S, Quintero G, López JA, Corradin G, Arévalo-Herrera M. Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. Int J Parasitol. 2004 Dec;34(13-14):1535-46.</citation>
    <PMID>15582530</PMID>
  </reference>
  <reference>
    <citation>Jordan-Villegas, A., et al., Cellular and humoral responses to Plasmodium vivax irradiated sporozoites in Aotus monkeys. (In preparation), 2007</citation>
  </reference>
  <reference>
    <citation>Hollingdale MR, Krzych U. Immune responses to liver-stage parasites: implications for vaccine development. Chem Immunol. 2002;80:97-124. Review.</citation>
    <PMID>12058653</PMID>
  </reference>
  <reference>
    <citation>Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science. 1980 Jan 4;207(4426):71-3.</citation>
    <PMID>6985745</PMID>
  </reference>
  <reference>
    <citation>Hollingdale MR, Nardin EH, Tharavanij S, Schwartz AL, Nussenzweig RS. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J Immunol. 1984 Feb;132(2):909-13.</citation>
    <PMID>6317752</PMID>
  </reference>
  <reference>
    <citation>Millet P, Chizzolini C, Pieniazek NJ, Charoenvit Y, Nakamura K, Aikawa M, Jones TR, Hoffman SL, Collins WE. A monoclonal antibody directed against the sporozoite stage of Plasmodium vivax binds to liver parenchymal cells. Immunol Lett. 1992 Aug;33(3):289-94.</citation>
    <PMID>1428005</PMID>
  </reference>
  <reference>
    <citation>Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature. 1989 Sep 28;341(6240):323-6.</citation>
    <PMID>2477703</PMID>
  </reference>
  <reference>
    <citation>Tsuji M, Romero P, Nussenzweig RS, Zavala F. CD4+ cytolytic T cell clone confers protection against murine malaria. J Exp Med. 1990 Nov 1;172(5):1353-7.</citation>
    <PMID>2146361</PMID>
  </reference>
  <reference>
    <citation>Tsuji M, Mombaerts P, Lefrancois L, Nussenzweig RS, Zavala F, Tonegawa S. Gamma delta T cells contribute to immunity against the liver stages of malaria in alpha beta T-cell-deficient mice. Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):345-9.</citation>
    <PMID>8278391</PMID>
  </reference>
  <reference>
    <citation>Renggli J, Hahne M, Matile H, Betschart B, Tschopp J, Corradin G. Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-I) or perforin-mediated cytotoxicity. Parasite Immunol. 1997 Mar;19(3):145-8.</citation>
    <PMID>9106820</PMID>
  </reference>
  <reference>
    <citation>Calvo-Calle JM, Hammer J, Sinigaglia F, Clavijo P, Moya-Castro ZR, Nardin EH. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J Immunol. 1997 Aug 1;159(3):1362-73.</citation>
    <PMID>9233633</PMID>
  </reference>
  <reference>
    <citation>Ferreira A, Schofield L, Enea V, Schellekens H, van der Meide P, Collins WE, Nussenzweig RS, Nussenzweig V. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science. 1986 May 16;232(4752):881-4.</citation>
    <PMID>3085218</PMID>
  </reference>
  <reference>
    <citation>Maheshwari RK, Czarniecki CW, Dutta GP, Puri SK, Dhawan BN, Friedman RM. Recombinant human gamma interferon inhibits simian malaria. Infect Immun. 1986 Sep;53(3):628-30.</citation>
    <PMID>3091507</PMID>
  </reference>
  <reference>
    <citation>Weiss WR, Berzofsky JA, Houghten RA, Sedegah M, Hollindale M, Hoffman SL. A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. J Immunol. 1992 Sep 15;149(6):2103-9.</citation>
    <PMID>1517574</PMID>
  </reference>
  <reference>
    <citation>Sedegah M, Finkelman F, Hoffman SL. Interleukin 12 induction of interferon gamma-dependent protection against malaria. Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10700-2.</citation>
    <PMID>7938013</PMID>
  </reference>
  <reference>
    <citation>Hoffman SL, Crutcher JM, Puri SK, Ansari AA, Villinger F, Franke ED, Singh PP, Finkelman F, Gately MK, Dutta GP, Sedegah M. Sterile protection of monkeys against malaria after administration of interleukin-12. Nat Med. 1997 Jan;3(1):80-3.</citation>
    <PMID>8986746</PMID>
  </reference>
  <reference>
    <citation>Fidock DA, Gras-Masse H, Lepers JP, Brahimi K, Benmohamed L, Mellouk S, Guerin-Marchand C, Londono A, Raharimalala L, Meis JF, et al. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J Immunol. 1994 Jul 1;153(1):190-204. Erratum in: J Immunol 1994 Dec 1;153(11):5347.</citation>
    <PMID>7515922</PMID>
  </reference>
  <reference>
    <citation>Good MF, Pombo D, Quakyi IA, Riley EM, Houghten RA, Menon A, Alling DW, Berzofsky JA, Miller LH. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci U S A. 1988 Feb;85(4):1199-203.</citation>
    <PMID>2448793</PMID>
  </reference>
  <reference>
    <citation>Guebre-Xabier M, Schwenk R, Krzych U. Memory phenotype CD8(+) T cells persist in livers of mice protected against malaria by immunization with attenuated Plasmodium berghei sporozoites. Eur J Immunol. 1999 Dec;29(12):3978-86.</citation>
    <PMID>10602007</PMID>
  </reference>
  <reference>
    <citation>López, J.A., et al., Immunogenicity of synthetic peptides corresponding to the nonrepeat regions of the P. falciparum circumsporozoite protein. Vaccines 96. Cold Spring Harbor Laboratory 1996: p. 255-260</citation>
  </reference>
  <reference>
    <citation>Perlaza BL, Arévalo-Herrera M, Brahimi K, Quintero G, Palomino JC, Gras-Masse H, Tartar A, Druilhe P, Herrera S. Immunogenicity of four Plasmodium falciparum preerythrocytic antigens in Aotus lemurinus monkeys. Infect Immun. 1998 Jul;66(7):3423-8.</citation>
    <PMID>9632616</PMID>
  </reference>
  <reference>
    <citation>Perlaza BL, Zapata C, Valencia AZ, Hurtado S, Quintero G, Sauzet JP, Brahimi K, Blanc C, Arévalo-Herrera M, Druilhe P, Herrera S. Immunogenicity and protective efficacy of Plasmodium falciparum liver-stage Ag-3 in Aotus lemurinus griseimembra monkeys. Eur J Immunol. 2003 May;33(5):1321-7.</citation>
    <PMID>12731057</PMID>
  </reference>
  <reference>
    <citation>Herrera S, Herrera MA, Certa U, Corredor A, Guerrero R. Efficiency of human Plasmodium falciparum malaria vaccine candidates in Aotus lemurinus monkeys. Mem Inst Oswaldo Cruz. 1992;87 Suppl 3:423-8.</citation>
    <PMID>1343722</PMID>
  </reference>
  <reference>
    <citation>Valderrama-Aguirre A, Quintero G, Gómez A, Castellanos A, Pérez Y, Méndez F, Arévalo-Herrera M, Herrera S. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):16-24.</citation>
    <PMID>16291762</PMID>
  </reference>
  <reference>
    <citation>Arévalo-Herrera M, Castellanos A, Yazdani SS, Shakri AR, Chitnis CE, Dominik R, Herrera S. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):25-31.</citation>
    <PMID>16291763</PMID>
  </reference>
  <reference>
    <citation>Jordan-Villegas A, Zapata JC, Perdomo AB, Quintero GE, Solarte Y, Arévalo-Herrera M, Herrera S. Aotus lemurinus griseimembra monkeys: a suitable model for Plasmodium vivax sporozoite infection. Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):10-5.</citation>
    <PMID>16291761</PMID>
  </reference>
  <reference>
    <citation>Herrera S, Bonelo A, Perlaza BL, Fernández OL, Victoria L, Lenis AM, Soto L, Hurtado H, Acuña LM, Vélez JD, Palacios R, Chen-Mok M, Corradin G, Arévalo-Herrera M. Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):3-9.</citation>
    <PMID>16291760</PMID>
  </reference>
  <reference>
    <citation>Fernández, O., et al. Development of a sporozoite challenge model for Plasmodium vivax in human volunteers. in Annual meeting 54th American Society of Tropical Medicine and Hygiene. December 11-15. . 2005. Washington: Am Trop J Med. Hyg.</citation>
  </reference>
  <reference>
    <citation>Arévalo-Herrera M, Herrera S. Plasmodium vivax malaria vaccine development. Mol Immunol. 2001 Dec;38(6):443-55. Review.</citation>
    <PMID>11741694</PMID>
  </reference>
  <reference>
    <citation>Castellanos A, Arévalo-Herrera M, Restrepo N, Gulloso L, Corradin G, Herrera S. Plasmodium vivax thrombospondin related adhesion protein: immunogenicity and protective efficacy in rodents and Aotus monkeys. Mem Inst Oswaldo Cruz. 2007 Jun;102(3):411-6.</citation>
    <PMID>17568948</PMID>
  </reference>
  <reference>
    <citation>Rogers WO, Gowda K, Hoffman SL. Construction and immunogenicity of DNA vaccine plasmids encoding four Plasmodium vivax candidate vaccine antigens. Vaccine. 1999 Aug 6;17(23-24):3136-44.</citation>
    <PMID>10462250</PMID>
  </reference>
  <reference>
    <citation>Stowers AW, Cioce V, Shimp RL, Lawson M, Hui G, Muratova O, Kaslow DC, Robinson R, Long CA, Miller LH. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect Immun. 2001 Mar;69(3):1536-46.</citation>
    <PMID>11179324</PMID>
  </reference>
  <reference>
    <citation>Collins WE, Kaslow DC, Sullivan JS, Morris CL, Galland GG, Yang C, Saekhou AM, Xiao L, Lal AA. Testing the efficacy of a recombinant merozoite surface protein (MSP-1(19) of Plasmodium vivax in Saimiri boliviensis monkeys. Am J Trop Med Hyg. 1999 Mar;60(3):350-6.</citation>
    <PMID>10466960</PMID>
  </reference>
  <reference>
    <citation>Oliveira-Ferreira J, Vargas-Serrato E, Barnwell JW, Moreno A, Galinski MR. Immunogenicity of Plasmodium vivax merozoite surface protein-9 recombinant proteins expressed in E. coli. Vaccine. 2004 May 7;22(15-16):2023-30.</citation>
    <PMID>15121316</PMID>
  </reference>
  <reference>
    <citation>Yazdani SS, Shakri AR, Mukherjee P, Baniwal SK, Chitnis CE. Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein. Vaccine. 2004 Sep 9;22(27-28):3727-37.</citation>
    <PMID>15315853</PMID>
  </reference>
  <reference>
    <citation>Kocken CH, Dubbeld MA, Van Der Wel A, Pronk JT, Waters AP, Langermans JA, Thomas AW. High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2. Infect Immun. 1999 Jan;67(1):43-9.</citation>
    <PMID>9864194</PMID>
  </reference>
  <reference>
    <citation>Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine. 2005 May 2;23(24):3131-8.</citation>
    <PMID>15837212</PMID>
  </reference>
  <reference>
    <citation>Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS, Suwanabun N, Torii M, Kaslow DC. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun. 2000 Dec;68(12):6618-23.</citation>
    <PMID>11083773</PMID>
  </reference>
  <reference>
    <citation>Arévalo-Herrera M, Solarte Y, Zamora F, Mendez F, Yasnot MF, Rocha L, Long C, Miller LH, Herrera S. Plasmodium vivax: transmission-blocking immunity in a malaria-endemic area of Colombia. Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):38-43.</citation>
    <PMID>16291765</PMID>
  </reference>
  <reference>
    <citation>Manzano, M.R., et al., Standardization of Anopheles albimanus infection with Plasmodium vivax for sporozoite challenge of naive volunteers. (In preparation), 2009.</citation>
  </reference>
  <reference>
    <citation>Snounou G. Detection and identification of the four malaria parasite species infecting humans by PCR amplification. Methods Mol Biol. 1996;50:263-91.</citation>
    <PMID>8751365</PMID>
  </reference>
  <reference>
    <citation>Baird JK, Tiwari T, Martin GJ, Tamminga CL, Prout TM, Tjaden J, Bravet PP, Rawlins S, Ferrel M, Carucci D, Hoffman SL. Chloroquine for the treatment of uncomplicated malaria in Guyana. Ann Trop Med Parasitol. 2002 Jun;96(4):339-48.</citation>
    <PMID>12171615</PMID>
  </reference>
  <reference>
    <citation>Ryan JR, Stoute JA, Amon J, Dunton RF, Mtalib R, Koros J, Owour B, Luckhart S, Wirtz RA, Barnwell JW, Rosenberg R. Evidence for transmission of Plasmodium vivax among a duffy antigen negative population in Western Kenya. Am J Trop Med Hyg. 2006 Oct;75(4):575-81.</citation>
    <PMID>17038676</PMID>
  </reference>
  <reference>
    <citation>Arévalo-Herrera M, Roggero MA, Gonzalez JM, Vergara J, Corradin G, López JA, Herrera S. Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys. Ann Trop Med Parasitol. 1998 Jul;92(5):539-51.</citation>
    <PMID>9797827</PMID>
  </reference>
  <reference>
    <citation>Herrera S, Escobar P, de Plata C, Avila GI, Corradin G, Herrera MA. Human recognition of T cell epitopes on the Plasmodium vivax circumsporozoite protein. J Immunol. 1992 Jun 15;148(12):3986-90.</citation>
    <PMID>1376347</PMID>
  </reference>
  <reference>
    <citation>Arévalo-Herrera M, Valencia AZ, Vergara J, Bonelo A, Fleischhauer K, González JM, Restrepo JC, López JA, Valmori D, Corradin G, Herrera S. Identification of HLA-A2 restricted CD8(+) T-lymphocyte responses to Plasmodium vivax circumsporozoite protein in individuals naturally exposed to malaria. Parasite Immunol. 2002 Mar;24(3):161-9.</citation>
    <PMID>12078650</PMID>
  </reference>
  <reference>
    <citation>Perlaza BL, Sauzet JP, Balde AT, Brahimi K, Tall A, Corradin G, Druilhe P. Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice. Eur J Immunol. 2001 Jul;31(7):2200-9.</citation>
    <PMID>11449374</PMID>
  </reference>
  <reference>
    <citation>Miller LH, Mason SJ, Dvorak JA, McGinniss MH, Rothman IK. Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science. 1975 Aug 15;189(4202):561-3.</citation>
    <PMID>1145213</PMID>
  </reference>
  <reference>
    <citation>Herrera S, Gómez A, Vera O, Vergara J, Valderrama-Aguirre A, Maestre A, Méndez F, Wang R, Chitnis CE, Yazdani SS, Arévalo-Herrera M. Antibody response to Plasmodium vivax antigens in Fy-negative individuals from the Colombian Pacific coast. Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):44-9.</citation>
    <PMID>16291766</PMID>
  </reference>
  <reference>
    <citation>Ocaña-Morgner C, Mota MM, Rodriguez A. Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med. 2003 Jan 20;197(2):143-51.</citation>
    <PMID>12538654</PMID>
  </reference>
  <reference>
    <citation>Coban C, Ishii KJ, Kawai T, Hemmi H, Sato S, Uematsu S, Yamamoto M, Takeuchi O, Itagaki S, Kumar N, Horii T, Akira S. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med. 2005 Jan 3;201(1):19-25.</citation>
    <PMID>15630134</PMID>
  </reference>
  <reference>
    <citation>Engwerda CR, Good MF. Interactions between malaria parasites and the host immune system. Curr Opin Immunol. 2005 Aug;17(4):381-7. Review.</citation>
    <PMID>15950450</PMID>
  </reference>
  <reference>
    <citation>Scheller LF, Azad AF. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4066-8.</citation>
    <PMID>7732032</PMID>
  </reference>
  <reference>
    <citation>Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature. 2005 Jan 13;433(7022):164-7. Epub 2004 Dec 5. Erratum in: Nature. 2007 Mar 1;446(7131):102.</citation>
    <PMID>15580261</PMID>
  </reference>
  <reference>
    <citation>Mangold KA, Manson RU, Koay ES, Stephens L, Regner M, Thomson RB Jr, Peterson LR, Kaul KL. Real-time PCR for detection and identification of Plasmodium spp. J Clin Microbiol. 2005 May;43(5):2435-40.</citation>
    <PMID>15872277</PMID>
  </reference>
  <reference>
    <citation>Baird JK, Lacy MD, Basri H, Barcus MJ, Maguire JD, Bangs MJ, Gramzinski R, Sismadi P, Krisin, Ling J, Wiady I, Kusumaningsih M, Jones TR, Fryauff DJ, Hoffman SL; United States Naval Medical Research Unit 2 Clinical Trials Team. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis. 2001 Dec 15;33(12):1990-7. Epub 2001 Nov 12.</citation>
    <PMID>11712091</PMID>
  </reference>
  <reference>
    <citation>Chatterjee S, François G, Druilhe P, Timperman G, Wéry M. Immunity to Plasmodium berghei exoerythrocytic forms derived from irradiated sporozoites. Parasitol Res. 1996;82(4):297-303.</citation>
    <PMID>8740544</PMID>
  </reference>
  <reference>
    <citation>Malkin E, Dubovsky F, Moree M. Progress towards the development of malaria vaccines. Trends Parasitol. 2006 Jul;22(7):292-5. Epub 2006 May 16.</citation>
    <PMID>16707275</PMID>
  </reference>
  <reference>
    <citation>Beier JC, Davis JR, Vaughan JA, Noden BH, Beier MS. Quantitation of Plasmodium falciparum sporozoites transmitted in vitro by experimentally infected Anopheles gambiae and Anopheles stephensi. Am J Trop Med Hyg. 1991 May;44(5):564-70.</citation>
    <PMID>2063960</PMID>
  </reference>
  <reference>
    <citation>Doolan DL, Hoffman SL. Pre-erythrocytic-stage immune effector mechanisms in Plasmodium spp. infections. Philos Trans R Soc Lond B Biol Sci. 1997 Sep 29;352(1359):1361-7. Review.</citation>
    <PMID>9355128</PMID>
  </reference>
  <reference>
    <citation>Doolan DL, Martinez-Alier N. Immune response to pre-erythrocytic stages of malaria parasites. Curr Mol Med. 2006 Mar;6(2):169-85. Review.</citation>
    <PMID>16515509</PMID>
  </reference>
  <reference>
    <citation>Hoffman, S.L., et al., Attacking the infected hepatocyte. In Malaria Vaccine Development: A Multi- Immune Response Approach, ed. S.L. Hoffman. 1996, Washington, DC: ASM Press. 35-75.</citation>
  </reference>
  <reference>
    <citation>Nussenzweig RS, Vanderberg JP, Most H, Orton C. Specificity of protective immunity produced by x-irradiated Plasmodium berghei sporozoites. Nature. 1969 May 3;222(5192):488-9.</citation>
    <PMID>5768632</PMID>
  </reference>
  <reference>
    <citation>Nardin EH, Nussenzweig RS, Altszuler R, Herrington D, Levine M, Murphy J, Davis J, Bathurst I, Barr P, Romero P, et al. Cellular and humoral immune responses to a recombinant P. falciparum CS protein in sporozoite-immunized rodents and human volunteers. Bull World Health Organ. 1990;68 Suppl:85-7.</citation>
    <PMID>2094595</PMID>
  </reference>
  <reference>
    <citation>Procell PM, Collins WE, Campbell GH. Circumsporozoite protein of the human malaria parasite Plasmodium ovale identified with monoclonal antibodies. Infect Immun. 1988 Feb;56(2):376-9.</citation>
    <PMID>3338845</PMID>
  </reference>
  <reference>
    <citation>Rathore D, Nagarkatti R, Jani D, Chattopadhyay R, de la Vega P, Kumar S, McCutchan TF. An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J Biol Chem. 2005 May 27;280(21):20524-9. Epub 2005 Mar 21.</citation>
    <PMID>15781464</PMID>
  </reference>
  <reference>
    <citation>Cox RJ, Brokstad KA, Zuckerman MA, Wood JM, Haaheim LR, Oxford JS. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine. 1994 Aug;12(11):993-9.</citation>
    <PMID>7975853</PMID>
  </reference>
  <reference>
    <citation>Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods. 2004 Mar;286(1-2):111-22.</citation>
    <PMID>15087226</PMID>
  </reference>
  <reference>
    <citation>Malaspina A, Moir S, Orsega SM, Vasquez J, Miller NJ, Donoghue ET, Kottilil S, Gezmu M, Follmann D, Vodeiko GM, Levandowski RA, Mican JM, Fauci AS. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis. 2005 May 1;191(9):1442-50. Epub 2005 Mar 24.</citation>
    <PMID>15809902</PMID>
  </reference>
  <reference>
    <citation>Palmer DR, Krzych U. Cellular and molecular requirements for the recall of IL-4-producing memory CD4(+)CD45RO(+)CD27(-) T cells during protection induced by attenuated Plasmodium falciparum sporozoites. Eur J Immunol. 2002 Mar;32(3):652-61.</citation>
    <PMID>11857339</PMID>
  </reference>
  <reference>
    <citation>Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol. 2004 Nov;4(11):841-55. Review.</citation>
    <PMID>15516964</PMID>
  </reference>
  <reference>
    <citation>Di Fabio S, Mbawuike IN, Kiyono H, Fujihashi K, Couch RB, McGhee JR. Quantitation of human influenza virus-specific cytotoxic T lymphocytes: correlation of cytotoxicity and increased numbers of IFN-gamma producing CD8+ T cells. Int Immunol. 1994 Jan;6(1):11-9.</citation>
    <PMID>8148319</PMID>
  </reference>
  <reference>
    <citation>Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoenvit Y, Carucci DJ, Hedstrom RC, Rahardjo N, Gay T, Hobart P, Stout R, Jones TR, Richie TL, Parker SE, Doolan DL, Norman J, Hoffman SL. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10817-22. Epub 2001 Aug 28.</citation>
    <PMID>11526203</PMID>
  </reference>
  <reference>
    <citation>Wang R, Epstein J, Charoenvit Y, Baraceros FM, Rahardjo N, Gay T, Banania JG, Chattopadhyay R, de la Vega P, Richie TL, Tornieporth N, Doolan DL, Kester KE, Heppner DG, Norman J, Carucci DJ, Cohen JD, Hoffman SL. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. J Immunol. 2004 May 1;172(9):5561-9.</citation>
    <PMID>15100299</PMID>
  </reference>
  <reference>
    <citation>Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJ, Kast WM. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol. 1993 Jun;23(6):1215-9.</citation>
    <PMID>7684681</PMID>
  </reference>
  <reference>
    <citation>Calvo-Calle JM, Oliveira GA, Nardin EH. Human CD4+ T cells induced by synthetic peptide malaria vaccine are comparable to cells elicited by attenuated Plasmodium falciparum sporozoites. J Immunol. 2005 Dec 1;175(11):7575-85.</citation>
    <PMID>16301667</PMID>
  </reference>
  <reference>
    <citation>Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics. 2000 Jun;155(2):945-59.</citation>
    <PMID>10835412</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2010</study_first_submitted>
  <study_first_submitted_qc>March 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2010</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Malaria Vaccine and Drug Development Center</investigator_affiliation>
    <investigator_full_name>Socrates Herrera Valencia</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>GCP Good Clinical Practice</keyword>
  <keyword>IFAT Indirect Immunofluorescence antibody test</keyword>
  <keyword>MFA Membrane Feeding Assay</keyword>
  <keyword>N Number (typically refers to subjects)</keyword>
  <keyword>RBC Red Blood Cells</keyword>
  <keyword>SOP Standard Operating Procedure</keyword>
  <keyword>TBS Thick blood smear</keyword>
  <keyword>P. Vivax</keyword>
  <keyword>irradiated sporozoite vaccination.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

